Summary:
- Researchers are investigating whether Metformin, a widely used first-line medication for Type 2 diabetes, possesses secondary properties that may slow down the biological aging process.
- The study examines the drug's potential impact on cellular mechanisms and molecular pathways associated with aging, suggesting that repurposing common pharmaceuticals could have significant implications for geriatric medicine and longevity research.